Clinical Trial Details
— Status: Withdrawn
Administrative data
NCT number |
NCT03714477 |
Other study ID # |
CRE 2018.276 |
Secondary ID |
|
Status |
Withdrawn |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 1, 2021 |
Est. completion date |
October 30, 2022 |
Study information
Verified date |
February 2021 |
Source |
Chinese University of Hong Kong |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Having the advantages of being minimally invasive and simple, extracorporeal shock wave
lithotripsy (SWL) remains one of the treatment options for renal stones less than 2cm.
Although SWL is the most minimally invasive surgical approach for stone, there are still some
concern about its short and long term side effect. While, there are some evidences that SWL
might lead to increase in new onset hypertension, investigator's recent study suggested it
might also cause worsening of blood pressure control in patient with known hypertension.
Therefore, further studies are needed to confirm the initial finding. This study recruits
patients who have hypertension and are currently diagnosed to have renal stone and planned
for SWL, in order to to investigate the effect of SWL on blood pressure control.
After informed consent and background information have been obtained, patients will be
randomized to either have routine SWL (treatment arm) or 6 months later (control arm). Group
1 patients will have blood pressure monitored for one day at home by an handy automated blood
pressure measuring machine before SWL and 6 months after SWL. Group 2 patients will have
blood pressure monitoring immediately and then 6 months later, just prior to the SWL.
Description:
BACKGROUND
Extracorporeal shock wave lithotripsy (SWL) was first introduced in early 1980's for the
management of urolithiasis. The advantage of being minimally invasive, when compared to other
procedures for stone treatment, made SWL remain one of the treatment options for renal stones
less than 2 cm in the latest guidelines.
Despite considered as the most non-invasive treatment for urinary calculi, there are still
many concerns about the long-term consequence of SWL. In particular, the effect of SWL on
blood pressure is still a controversy topic. In the recent study, investigator has observed
approximately 20% of subjects experienced worsened blood pressure control during the 2-year
follow-up period, including 20/202 (9.95%) previously non-hypertensive subjects who developed
new onset hypertension. The observed incidence of new-onset hypertension was quite similar
those in some reported series. In the literature, there were multiple reports, including case
series and hospital data analyses, 7-9 of development of new-onset hypertension after SWL.
Unfortunately, most of those studies were retrospective and used different definitions of
hypertension.
But the high incidence of worsening blood pressure control, including 43 (36.4%) of 118
hypertensive subjects who required add-on antihypertensive therapies, observed in our study
was alarming. Because most studies in the literature were just focused on development of
new-onset hypertension, investigator's observation provides supplementary information about
potential effects of SWL on pre-existing hypertension. In general, the average annual
incidence of add-on pharmacotherapy among local hypertensive patients was 4.71-6.41%. 10
Therefore, the add-on therapy rate of 36.4% during the 2-year follow-up was much higher than
that in the general population. Unfortunately, investigator did not include a
non-interventional arm for comparison in the previous study and could not conclude that this
outcome was solely attributable to SWL.
Therefore, investigator would like to propose a prospective study to assess the effect SWL on
the blood pressure control in patients with known hypertension. Investigator hope the study
results will provide additional information on the long-term effect of SWL on patients.
OJECTIVES
To investigate the effect of extracorporeal shockwave lithotripsy on the effect of change in
blood pressure in patients with known hypertension.
STUDY PROTOCOL:
Patients fulfilled the inclusion and exclusion criteria specific to this study will be
prospectively recruited. After obtaining informed consent, patients will be randomized to
either treatment group or control group.
Baseline information, including age, years of diagnosed to have hypertension, current medical
usage, other comorbidities, BMI etc. will be collected from patients. All SWL would be
performed in the Lithotripsy and Uro-investigation Centre of the Prince of Wales Hospital,
and treated by Modulith SLX-F2 Connect (Storz Medical, Switzerland), an electromagnetic
lithotriptor. The treatment would be performed as standard care in our hospital. After SWL,
the patient would be follow-up in clinic as usual. During the 6 months study period, patients
are strongly advised to avoid change in hypertensive medication.
Blood pressure assessment:
During each blood pressure assessment, the following procedure will be performed:
1. 24-hour blood pressure monitoring - 24-h non-invasive ambulatory BP and HR monitoring
was performed using a validated device and followed the recommended approached. 11 The
blood pressure measurement would be programmed to measure BP every 15 min. Each
recording will be started in the morning and performed throughout a full 24-h period,
during which subjects are allowed to follow their normal daily routine. The analysis of
24-h BP recordings are preceded by removal of artifacts, according to previously
described editing criteria. 12 Recordings are excluded from the analysis when > 10% of
all readings or more than one reading per hour is missed. Computed analysis of the
individual recordings provided 24-h, night-time (23.00-07.00 h), morning-time
(0.7.00-12.00 h), and afternoon/evening-time (12.00- 23.00 h) mean values of SBP, DBP,
and HR.
2. Clinic blood pressure measurement At each visit, blood pressure will be measured after
patient rested for more than 10 minutes, with repeated measurement 5 minutes apart. The
mean blood pressure will be recorded.
3. Any changes in antihypertensive drugs and reasons
4. Any adverse events.
The result collected will be used for further analysis